289 related articles for article (PubMed ID: 28860188)
21. Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9.
Appleby TC; Greenstein AE; Hung M; Liclican A; Velasquez M; Villaseñor AG; Wang R; Wong MH; Liu X; Papalia GA; Schultz BE; Sakowicz R; Smith V; Kwon HJ
J Biol Chem; 2017 Apr; 292(16):6810-6820. PubMed ID: 28235803
[TBL] [Abstract][Full Text] [Related]
22. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinases: fold and function of their catalytic domains.
Tallant C; Marrero A; Gomis-Rüth FX
Biochim Biophys Acta; 2010 Jan; 1803(1):20-8. PubMed ID: 19374923
[TBL] [Abstract][Full Text] [Related]
24. Isothiazolones interfere with normal matrix metalloproteinase activation and inhibit cartilage proteoglycan degradation.
Arner EC; Pratta MA; Freimark B; Lischwe M; Trzaskos JM; Magolda RL; Wright SW
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):417-24. PubMed ID: 8809028
[TBL] [Abstract][Full Text] [Related]
25. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
[TBL] [Abstract][Full Text] [Related]
26. Endostatin binds to the catalytic domain of matrix metalloproteinase-2.
Lee SJ; Jang JW; Kim YM; Lee HI; Jeon JY; Kwon YG; Lee ST
FEBS Lett; 2002 May; 519(1-3):147-52. PubMed ID: 12023034
[TBL] [Abstract][Full Text] [Related]
27. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
[TBL] [Abstract][Full Text] [Related]
28. Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.
Arkadash V; Yosef G; Shirian J; Cohen I; Horev Y; Grossman M; Sagi I; Radisky ES; Shifman JM; Papo N
J Biol Chem; 2017 Feb; 292(8):3481-3495. PubMed ID: 28087697
[TBL] [Abstract][Full Text] [Related]
29. Activation of membrane-type matrix metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-Golgi network.
Kang T; Nagase H; Pei D
Cancer Res; 2002 Feb; 62(3):675-81. PubMed ID: 11830519
[TBL] [Abstract][Full Text] [Related]
30. Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3.
Geurts N; Martens E; Van Aelst I; Proost P; Opdenakker G; Van den Steen PE
Biochemistry; 2008 Feb; 47(8):2689-99. PubMed ID: 18237197
[TBL] [Abstract][Full Text] [Related]
31. Fluorescence quenching studies of matrix metalloproteinases (MMPs): evidence for structural rearrangement of the proMMP-2/TIMP-2 complex upon mercurial activation.
Stack MS; Itoh Y; Young TN; Nagase H
Arch Biochem Biophys; 1996 Sep; 333(1):163-9. PubMed ID: 8806767
[TBL] [Abstract][Full Text] [Related]
32. New in Vivo Compatible Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitors.
Beutel B; Song J; Konken CP; Korpos E; Schinor B; Gerwien H; Vidyadharan R; Burmeister M; Li L; Haufe G; Sorokin L
Bioconjug Chem; 2018 Nov; 29(11):3715-3725. PubMed ID: 30277751
[TBL] [Abstract][Full Text] [Related]
33. Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases.
Nakamura H; Fujii Y; Ohuchi E; Yamamoto E; Okada Y
Eur J Biochem; 1998 Apr; 253(1):67-75. PubMed ID: 9578462
[TBL] [Abstract][Full Text] [Related]
34. Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14.
Shirian J; Arkadash V; Cohen I; Sapir T; Radisky ES; Papo N; Shifman JM
FEBS Lett; 2018 Apr; 592(7):1122-1134. PubMed ID: 29473954
[TBL] [Abstract][Full Text] [Related]
35. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
Senn N; Ott M; Lanz J; Riedl R
J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological implications of MMP-9 inhibition by ACE inhibitors.
Yamamoto D; Takai S
Curr Med Chem; 2009; 16(11):1349-54. PubMed ID: 19355890
[TBL] [Abstract][Full Text] [Related]
37. Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 cascade.
Dreier R; Grässel S; Fuchs S; Schaumburger J; Bruckner P
Exp Cell Res; 2004 Jul; 297(2):303-12. PubMed ID: 15212936
[TBL] [Abstract][Full Text] [Related]
38. Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides.
Dufour A; Zucker S; Sampson NS; Kuscu C; Cao J
J Biol Chem; 2010 Nov; 285(46):35944-56. PubMed ID: 20837483
[TBL] [Abstract][Full Text] [Related]
39. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.
Rashid ZA; Bardaweel SK
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509
[TBL] [Abstract][Full Text] [Related]
40. Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 Inhibitors.
Nuti E; Cuffaro D; D'Andrea F; Rosalia L; Tepshi L; Fabbi M; Carbotti G; Ferrini S; Santamaria S; Camodeca C; Ciccone L; Orlandini E; Nencetti S; Stura EA; Dive V; Rossello A
ChemMedChem; 2016 Aug; 11(15):1626-37. PubMed ID: 27356908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
